Patient Power®
Get Email Alerts!
Health Topics
Chronic Myelogenous Leukemia (CML) Health Center
Health Center Home About Our CML Education Center About CML Living with CML Patient Stories Support and Resources News and Views Sign up for...
Search by Keyword:
Search by Health Topic:
View all Health Topics >
2/24/12

Exploring Disease Risk and Treatment Options for CML

Dr. Michael Deininger, chief of hematology at the Huntsman Cancer Institute at the University of Utah, explores ongoing research to fine-tune treatment for CML. Dr. Deininger discusses second-generation TKIs in frontline therapy, considerations for switching or ceasing medication, and the need to refine molecular testing into a sophisticated, reliable prognostic method.

Get Email Updates:

Get updated automatically when new content about Chronic Myelogenous Leukemia has been posted.
Privacy Policy
Chronic Myelogenous Leukemia

Experts & Guests

Michael Deininger, M.D., Ph.D. Michael Deininger, M.D., Ph.D.
Chief of Hematology and Hematologic Malignancies , University of Utah, Huntsman Cancer Institute
Michael Deininger, MD, PhD, is chief of Hematology and Hematologic Malignancies for Huntsman Cancer Institute (HCI) at the University of Utah. He is a professor in the Department of Medicine at the University of Utah. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly... more >

Transcript

  1. Exploring Disease Risk and Treatment Options for CML

Related Videos

Dr. Michael Mauro explains the questions patients and their physicians should be asking themselves.

Watch Now
Dr. Neil Shah explains molecular response and treatment interruption updates from ASH 2011

Watch Now
Dr. Druker shares his passion and optimism for the continued advancement of CML research and treatment.

Watch Now